Key points are not available for this paper at this time.
Artificial intelligence and machine learning have demonstrated their potential role in predictive chemistry and synthetic planning of small molecules; there are at least a few reports of companies employing in silico synthetic planning into their overall approach to accessing target molecules. A data-driven synthesis planning program is one component being developed and evaluated by the Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) consortium, comprising MIT and 13 chemical and pharmaceutical company members. Together, we wrote this perspective to share how we think predictive models can be integrated into medicinal chemistry synthesis workflows, how they are currently used within MLPDS member companies, and the outlook for this field.
Building similarity graph...
Analyzing shared references across papers
Loading...
Thomas J. Struble
Merck & Co., Inc., Rahway, NJ, USA (United States)
Juan C. Alvarez
Merck & Co., Inc., Rahway, NJ, USA (United States)
Scott P. Brown
Eli Lilly (United States)
Journal of Medicinal Chemistry
Pfizer (United States)
Merck & Co., Inc., Rahway, NJ, USA (United States)
Eli Lilly (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Struble et al. (Fri,) studied this question.
synapsesocial.com/papers/69e33ddcdfa4bcab6eb736ee — DOI: https://doi.org/10.1021/acs.jmedchem.9b02120